References
- Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Dibartolomeo M, . Safety and efficacy of first line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009;20:1842–7.
- Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69:25–33.
- Heinzeling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: Incidence, etiology, and management. Curr Surg 2006;63: 334–7.
- Kesmodel SB, Ellis LM, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, . Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008;26:5254–60.
- Collins D, Ridgway PF, Winter DC, Fennelly D, Evroy D. Gastrointestinal perforation in metastatic carcinoma: A complication of bevacizumab therapy. Eur J Surg Oncol 2009; 35:444–6.
- Bège T, Lelong B, Viret F, Turrini O, Guiramand J, Topart D, . Bevacizumab-related surgical site complications despite primary resection in colorectal cancer patients. Ann Surg Oncol 2009;16:856–60.
- Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int 2004;66:924–34.
- Ramon J, Rimon U, Garniek A, Golan G, Bensaid P, Kitrey ND, . Renal angiomyolipomata: Long-term results following selective arterial embolization. Eur Urol 2009;55: 155–62.
- Kothary N, Soulen MC, Clark TW, Wein AJ, Shlansky-Goldberg RD, Crino PB, . Renal angiomyolipomata: Long-term results after arterial embolization. J Vasc Interv Radiol 2005;16:45–50.